ClinicalTrials.gg
RecruitingNCT06988579Updated Jun 26, 2025

The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening

An interventional study of AI in Lung Cancer, Artificial Intelligence (AI) and Randomized Controlled Trial, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jul 2024, registered May 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
7,294
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University — 20 open to participants now, 20 under way, none of them phase 3. Lung Neoplasms · The First Affiliated Hospital of Guangzhou Medical University.

Planned enrollment
4th of 18
7,294 · median 110
Started
2024
with 5 others
No phase
12 of 26
9 open now
Primary completion
2025-10
later than 4 of 19 live
Registered
13th of 26
by date

Among the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 13th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

20 of the 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 40 Years to 74 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lung Neoplasms by The First Affiliated Hospital of Guangzhou Medical University, or all of them as a file.
02

Study summary

AI diagnostic systems show great promise for improving lung cancer screening in community healthcare settings. While not originally designed for primary care, these tools demonstrate capabilities in nodule detection and workflow optimization. However, their effectiveness in resource-limited community centers requires thorough evaluation.

This RCT compares AI-assisted versus manual CT interpretation across community health centers. Expert radiologists will establish reference standards, while an independent committee blindly evaluates cases from both groups. The study assesses diagnostic accuracy, operational efficiency, and cost-effectiveness, with blinded analysts resolving discrepancies through consensus to ensure reliable results.

Read the detailed description

Artificial intelligence (AI) technologies, particularly advanced medical imaging analysis systems like the AI diagnostic platform evaluated in this study, demonstrate significant potential for enhancing lung cancer screening programs in community healthcare settings.Although this AI system was not originally designed specifically for primary care implementation, it has shown promising capabilities in various clinical applications, including nodule detection, malignancy risk stratification, and workflow optimization in radiology departments. However, its effectiveness in improving screening accuracy and operational efficiency in resource-limited community health centers remains to be thoroughly investigated.

Lung cancer screening and diagnosis involve complex clinical processes,including image interpretation, risk factor assessment, and follow-up decision-making. Implementing AI tools like this diagnostic platform in community screening programs could potentially improve detection rates, standardize interpretations, and optimize resource allocation. Nevertheless, the system has not been rigorously validated for use in primary care settings and may carry limitations in generalizability across diverse patient populations and imaging equipment variations. Inappropriate implementation could lead to diagnostic errors or inefficient resource utilization. Therefore, evaluating how such AI systems can effectively support community-based screening while maintaining diagnostic accuracy and cost-effectiveness is of paramount importance.

In this randomized controlled trial, participating community health centers will be allocated to either an AI-assisted interpretation group or a conventional manual interpretation group. All screening cases will undergo standardized low-dose CT imaging, with results interpreted through the respective group's designated method. A panel of three expert radiologists will establish reference standards for all cases, while an independent review committee will blindly evaluate a subset of cases from both groups to assess interpretation consistency. The evaluation will focus on diagnostic performance metrics, operational efficiency parameters, and cost-effectiveness indicators. Two separate analyst teams, blinded to group assignments, will process and compare the outcomes using predefined statistical methods, with any discrepancies resolved through consensus discussions to ensure data reliability.

03

Conditions studied

  • Lung Cancer
  • Artificial Intelligence (AI)
  • Randomized Controlled Trial

Browse trials for

04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 45-74 years
  2. Permanent resident of participating study communities
  3. No prior history of lung cancer and no lung cancer screening within the past 3 months
  4. Able to comprehend and voluntarily sign , with willingness to participate in long-term follow-up

Exclusion criteria

Exclusion Criteria:

  1. Individuals with a confirmed diagnosis of lung cancer
  2. Those with severe comorbidities contraindicating CT imaging
  3. Inability to understand study protocols or provide due to cognitive impairment
  4. Concurrent participation in other clinical trials that may interfere with study outcomes
  5. Unable to comply with follow-up requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
7,294 participants (estimated)

Study arms

  • Experimental
    AI-Assisted Group

    The AI-assisted group utilized AI-powered diagnostic software for interpreting low-dose computed tomography (LDCT) scans

    Other: AI

  • No intervention
    The manual interpretation group

    The manual interpretation group relied on standard radiologist evaluation for analyzing low-dose computed tomography (LDCT) scans.

Interventions

  • OtherAI

    An integrated AI-human collaborative workflow for lung cancer screening interpretation

06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy

    Sensitivity and Specificity: Comparison of AI-assisted versus manual interpretation in detecting malignant pulmonary nodules, validated against histopathological confirmation or 12-month clinical follow-up. Early Detection Rate: Proportion of stage I/II lung cancers correctly identified by each method.

    Time frame: One year after entry

  2. Interpretation Consistency

    Inter-reader Agreement: Measured by Cohen's kappa (κ) between AI-assisted radiologists and the independent review committee (IRC). Intra-reader Variability: Consistency of nodule classification in repeat readings (subset analysis).

    Time frame: One year after entry

Secondary outcomes

  1. Cost-Effectiveness

    Resource Utilization: Comparative analysis of staffing, equipment, and follow-up costs per detected cancer case. Incremental Cost per QALY (Quality-Adjusted Life Year): Long-term economic impact modeling.

    Time frame: One year after entry

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 15 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 25, 2025
StartActual
Jul 1, 2024
Primary completionEst.
Oct 31, 2025
CompletionEst.
Jan 7, 2026
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06988579
Responsible party
Jianxing He (Professor, The First Affiliated Hospital of Guangzhou Medical University) — Principal investigator
First posted
May 25, 2025
Start date
Jul 1, 2024
Primary completion
Oct 31, 2025 (estimated)
Completion
Jan 7, 2026 (estimated)
Last update
Jun 26, 2025

Study contacts

Jianxing He
Contact
drjianxing.he@gmail.com
+8618320729913

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion